Download presentation
Presentation is loading. Please wait.
1
Progress of the NSCLC Revolution
2
Agenda
3
Molecular Testing in NSCLC: Where Are We Going?
4
The NGS Era in France
5
Current Molecular Testing Guidelines
6
Tumor Responses to Crizotinib in ROS1-Rearranged NSCLC
7
First-Line Dabrafenib-Trametinib in BRAF-Positive NSCLC: PFS
8
The Potential of Precision Medicine
9
Faculty Commentary NGS and Testing
10
Molecular Testing Workflow
11
Comparison of Testing Methods
12
Faculty Commentary: Testing and Treatments
13
Summary of Frontline Immunotherapy Trials
14
Lack of Correlation Between TMB and PD-L1
15
Treating New Molecular Targets in NSCLC: How Are We Progressing?
16
Smoking Status in Patients With Uncommon Mutations
17
Overview of Select cMET Inhibitors: MET Amplification as a Target
18
Overview of Select cMET Inhibitors: MET Exon 14 Mutations as a Target
19
Overview of Select ERBB2/HER2 Inhibitors: HER2 Exon 20 Mutations as a Target
20
Overview of Select ERBB2/HER2 Inhibitors: HER2 Amplification as a Target
21
Overview of Select RET Inhibitors
22
Other RET Inhibitors of Interest in Early Trials
23
Data on TRK Inhibitors
24
Resistance Mechanisms
25
Immunotherapy in NSCLC: Where Have We Got To?
26
Monotherapy With Immunotherapy
27
Combination Chemotherapy and Immunotherapy
28
Emerging Data From IMpower132
29
CheckMate 227 Trial Design
30
Nivolumab Combinations: CheckMate 227
31
Frontline Immunotherapy in EGFR-Positive Patients
32
Second-Line Immunotherapy in EGFR/ALK-Positive Patients
33
Abbreviations
34
Abbreviations (cont)
35
Abbreviations (cont)
36
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.